Bispecific BCMA/CD19 targeted CAR-T cell therapy forces sustained disappearance of symptoms and anti-acetylcholine receptor antibodies in refractory myasthenia gravis: a case report.
Zhang Y, Liu D, Zhang Z, Huang X, Cao J, Wang G, Du X, Wang Z, Yang M, Luo T, Liu S, Zhang W, Sheng Y, Li H, Zhang W, Chen H, Zhang S, Wang X, Meng W, Zong S, Shi M, Zheng J, Cui G.
Zhang Y, et al. Among authors: zheng j.
J Neurol. 2024 Apr 11. doi: 10.1007/s00415-024-12367-4. Online ahead of print.
J Neurol. 2024.
PMID: 38602546
No abstract available.